Cost effectiveness analysis of etanercept (ENBREL) versus infliximab (Remicade) in the treatment of rheumatoid arthritis patients.

被引：0
|
作者：
Malone, DC
Ortmeier, BG
机构：
[1] Univ Arizona, Tucson, AZ USA
[2] Immunex Corp, Tucson, AZ USA
来源：
ARTHRITIS AND RHEUMATISM | 2002年 / 46卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S95 / S95
页数：1
相关论文
共 50 条
  • [21] A difference in effectiveness between infliximab, etanercept and adalimumab in patients with rheumatoid arthritis.
    Kievit, Wietske
    Fransen, Jaap
    Kuper, Ina H.
    van de Laar, Mart A. F. J.
    Jansen, Tim L.
    De Rooij, Dirk jan R. A. M.
    de Gendt, Carla M.
    Ronday, Karel H.
    Brus, Herman L. M.
    van Ooijen, Piet C. M.
    van Riel, Piet C. L. M.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S309 - S310
  • [22] A Cost-Cost Study Comparing Etanercept with Infliximab in Rheumatoid Arthritis
    Mark J. C. Nuijten
    Peter Engelfriet
    Klaas Duijn
    George Bruijn
    David Wierz
    Marc Koopmanschap
    PharmacoEconomics, 2001, 19 : 1051 - 1064
  • [23] A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis
    Nuijten, MJC
    Engelfriet, P
    Duijn, K
    Bruijn, G
    Wierz, D
    Koopmanschap, M
    PHARMACOECONOMICS, 2001, 19 (10) : 1051 - 1064
  • [24] COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN INSTITUTIONAL MARKET IN ECUADOR
    Albuja, M. F.
    Torres, F. G.
    Mould, J.
    Estevez, C.
    VALUE IN HEALTH, 2013, 16 (07) : A717 - A717
  • [25] Etanercept (Enbrel®) in patients with rheumatoid arthritis with recent onset versus established disease:: Improvement in disability
    Baumgartner, SW
    Fleischmann, RM
    Moreland, LW
    Schiff, MH
    Markenson, J
    Whitmore, JB
    JOURNAL OF RHEUMATOLOGY, 2004, 31 (08) : 1532 - 1537
  • [26] LONG-TERM COST-EFFECTIVENESS ANALYSIS OF THE TREATMENT WITH INFLIXIMAB, ETANERCEPT AND ADALIMUMAB IN RHEUMATOID ARTHRITIS PATIENTS IN REAL-LIFE CLINICAL PRACTICE
    Cardenas, M.
    de la Fuente, S.
    Font-Ugalde, P.
    Castro-Villegas, M. C.
    Romero-Gomez, M.
    Ruiz-Vilchez, D.
    Calvo-Gutierrez, J.
    Ortega-Castro, R.
    Escudero-Contreras, A.
    Casado, M. A.
    Collantes, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 703 - 703
  • [27] A threshold cost-effectiveness comparison of infliximab and etanercept in adults with rheumatoid arthritis in the UK.
    Bansback, N
    Brennan, A
    Conway, P
    Reynolds, AV
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S582 - S582
  • [28] Cost minimization analysis of rituximab versus infliximab, adalimumab and etanercept for rheumatoid arthritis from a payer perspective in Brazil
    Saggia, M. G.
    Santos, E. A.
    Nasciben, V
    VALUE IN HEALTH, 2007, 10 (06) : A247 - A247
  • [29] Cost effectiveness of infliximab in rheumatoid arthritis.
    Kavanaugh, A
    Patel, KK
    Bala, M
    Noe, L
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S144 - S144
  • [30] Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure
    Sonja Merkesdal
    Timm Kirchhoff
    Diane Wolka
    Gunter Ladinek
    Adrian Kielhorn
    Andrea Rubbert-Roth
    The European Journal of Health Economics, 2010, 11 : 95 - 104
12345